A Study of Recombinant Human Erythropoietin in Anemic Cancer Patients Undergoing Chemotherapy

Chugai Pharmaceutical104 enrolled

Overview

The purpose of this study is to evaluate the effectiveness and safety of recombinant human erythropoietin in anemic cancer patients undergoing chemotherapy.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

104

Conditions

Chemotherapy Induced Anemia

Interventions

recombinant human erythropoietinDRUG

3600IU(s.c.)/week for 7 weeks and 54000IU(s.c.)/week for 5 weeks

recombinant human erythropoietinDRUG

36000IU(s.c.)/week for 12 weeks

Eligibility

Sex: ALLMin age: 20 YearsMax age: 79 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Cancer patients Exclusion Criteria: * a history of myocardial, cerebral or pulmonary infarction * severe hypertension beyond control by drugs

Outcomes

Primary Outcomes

The increase in Hb concentration

Time frame: Day 28th or later

Secondary Outcomes

Changes in QOL scores

Time frame: 84 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.